Artur Widak | NurPhoto | Getty’s paintings
Johnson & Johnson on Tuesday reported adjusted profits and revenue that beat Wall Street expectations and raised its full-year forecast, citing strong growth across all business units led by its pharmaceuticals division.
J&J, whose financial results are considered leading for a lot of health corporations, said its first-quarter sales were up 5.6% in comparison with the identical quarter last yr.
The patron goods giant reported a net lack of $68 million, or 3 cents per share, related to talc liabilities and costs related to the upcoming spin-off of its consumer health business. This compares to net income of $5.2 billion, or $1.93 per share, for a similar period a yr ago. Excluding certain items, adjusted earnings per share were $2.68 for a time frame.
Here’s how J&J’s results compare to Wall Street expectations, based on an analyst survey by Refinitiv:
- Earnings per share: Adjusted $2.68 versus expected $2.50
- Income: USD 24.75 billion in comparison with the expected USD 23.67 billion
J&J currently forecasts 2023 sales of between $97.9 billion and $98.9 billion, about $1 billion greater than guidance given in January. The corporate raised its full-year adjusted earnings forecast to $10.60 to $10.70 per share, from a previous forecast of $10.45 to $10.65.
The corporate’s shares rose by almost 1% in pre-session trading. Shares are down greater than 6% within the yr to Monday’s close, giving the corporate a market value of around $430 billion.
CFO Joseph Wolk told CNBC on Tuesday that J&J had raised its guidelines resulting from strong growth in all three business sectors – consumer health, pharmaceuticals and medical devices.
“Should you take into consideration how we began the yr and guidelines in January, we were responsibly careful,” he told Squawk Box. “Growth in the primary quarter was much stronger than even within the fourth quarter for all three business units, and our stance is changing to responsibly optimistic at this point. We feel superb about 2023.”
He added that data on J&J’s cancer drug are being developed multiple myeloma and procedural data within the medical device division make the corporate “think very, thoroughly about what 2023 will bring.”
J&J reported $13.4 billion in pharmaceutical sales, up greater than 4% over the identical quarter last yr. The corporate says the expansion was driven by sales of Darzalex, a biologics used to treat multiple myeloma, and blockbuster Stelara, which is used to treat a spread of immune-mediated inflammatory diseases. But the corporate will lose patent protection for Stelara later this yr.
Sales in the corporate’s medical device business rose to almost $7.5 billion, up 7.3% from the primary quarter of 2022. J&J said acquisition of Abiomedthe cardiovascular medical technology company, last December fueled that growth.
J&J’s consumer health division, which is popping right into a separate publicly traded company this yr, reported roughly $3.8 billion in sales. This unit grew 7.4% over the identical period last yr, driven mainly by over-the-counter products resembling Tylenol and skincare products under brand names resembling Neutrogena and Aveeno.
Wolk told CNBC that the corporate is making “great strides” in separating its consumer health business. But J&J has not clarified when precisely the split will happen.
J&J also announced that its board of directors approved a quarterly dividend increase of 5.3% to $1.19 per share resulting from the corporate’s strong 2022 performance.
The Recent Brunswick, Recent Jersey-based company entered this profit season with a surge in its stock after offering more clarity over a long-running legal battle over baby talc-based products. Earlier this month, J&J offered to pay nearly $9 billion over the following 25 years to settle 1000’s of allegations that its baby powder and other talc products cause cancer.
J&J will hold an earnings call at 8:30 a.m. EST